PAPER García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R
SEARCH RESULTS
331254 RESULTS
PAPER Lemkul JA, Bevan DR
The Role of Molecular Simulations in the Development of Inhibitors of Amyloid β-Peptide Aggregation for the Treatment of Alzheimer's Disease.
ACS Chem Neurosci. 2012 Nov 21;3(11):845-56. PubMed: 23173066PAPER Smith B, Medda F, Gokhale V, Dunckley T, Hulme C
Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?
ACS Chem Neurosci. 2012 Nov 21;3(11):857-72. PubMed: 23173067PAPER Fernández-Morales JC, Arranz-Tagarro JA, Calvo-Gallardo E, Maroto M, Padín JF, García AG
Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease.
ACS Chem Neurosci. 2012 Nov 21;3(11):873-83. PubMed: 23173068PAPER Tarr JC, Turlington ML, Reid PR, Utley TJ, Sheffler DJ, Cho HP, Klar R, Pancani T, Klein MT, Bridges TM, Morrison RD, Blobaum AL, Xiang Z, Daniels JS, Niswender CM, Conn PJ, Wood MR, Lindsley CW
Targeting Selective Activation of M(1) for the Treatment of Alzheimer's Disease: Further Chemical Optimization and Pharmacological Characterization of the M(1) Positive Allosteric Modulator ML169.
ACS Chem Neurosci. 2012 Nov 21;3(11):884-95. PubMed: 23173069PAPER Gessel MM, Bernstein S, Kemper M, Teplow DB, Bowers MT
Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization.
ACS Chem Neurosci. 2012 Nov 21;3(11):909-18. Epub 2012 Jun 26 PubMed: 23173071PAPER Lincoln KM, Richardson TE, Rutter L, Gonzalez P, Simpkins JW, Green KN
An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation.
ACS Chem Neurosci. 2012 Nov 21;3(11):919-27. PubMed: 23173072PAPER Soper JH, Sugiyama S, Herbst-Robinson K, James MJ, Wang X, Trojanowski JQ, Smith AB, Lee VM, Ballatore C, Brunden KR
Brain-Penetrant Tetrahydronaphthalene Thromboxane A2-Prostanoid (TP) Receptor Antagonists as Prototype Therapeutics for Alzheimer's Disease.
ACS Chem Neurosci. 2012 Nov 21;3(11):928-40. PubMed: 23173073PAPER Naldi M, Fiori J, Pistolozzi M, Drake AF, Bertucci C, Wu R, Mlynarczyk K, Filipek S, De Simone A, Andrisano V
Amyloid β-Peptide 25-35 Self-Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment.
ACS Chem Neurosci. 2012 Nov 21;3(11):952-62. PubMed: 23173074PAPER Velasco PT, Heffern MC, Sebollela A, Popova IA, Lacor PN, Lee KB, Sun X, Tiano BN, Viola KL, Eckermann AL, Meade TJ, Klein WL
Synapse-Binding Subpopulations of Aβ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies.
ACS Chem Neurosci. 2012 Nov 21;3(11):972-81. PubMed: 23173076PAPER Schölzel-Dorenbos CJ, Arons AM, Wammes JJ, Rikkert M, Krabbe PF
Validation study of the prototype of a disease-specific index measure for health-related quality of life in dementia.
Health Qual Life Outcomes. 2012;10:118. PubMed: 23009579PAPER Sussman F, Villaverde MC, Domínguez JL, Danielson UH
On the Active Site Protonation State in Aspartic Proteases: Implications for Drug Design.
Curr Pharm Des. 2012 Nov 20; PubMed: 23170891PAPER
Clinical and biomarker changes in Alzheimer's disease.
PLoS One. 2012;7(11):e49876. PubMed: 23171103PAPER Laske C
Clinical and biomarker changes in Alzheimer's disease.
N Engl J Med. 2012 Nov 22;367(21):2050; author reply 2051-2. PubMed: 23171104PAPER Florez JC
Clinical and biomarker changes in Alzheimer's disease.
N Engl J Med. 2012 Nov 22;367(21):2051; author reply 2051-2. PubMed: 23171106Current Filters
No filters selected